Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02009397
Title A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors James Graham Brown Cancer Center
Age Groups: adult
Covered Countries USA

No variant requirements are available.